SCHEMBL2009782

SCHEMBL2009782

CC(C)(C)OC(=O)NCC(=O)c1ccc(OCC(=O)OCc2ccccc2)cc1O

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.48
MAOB P27338 1/20 0.46
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
LMNA P02545 2/20 0.44
SYK P43405 1/20 0.44
KDM4E B2RXH2 1/20 0.44
POLB P06746 1/20 0.44
KDM5A P29375 1/20 0.41
MAPT P10636 3/20 0.40
TP53 P04637 1/20 0.40
KLK7 P49862 1/20 0.40
KLK5 Q9Y337 1/20 0.40
ALDH1A1 P00352 1/20 0.40
PPARD Q03181 1/20 0.39
ATM Q13315 1/20 0.39
IDO1 P14902 1/20 0.39
CASP1 P29466 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2012183 0.88 HPGD (0.55) HPGDMEN1KMT2ALMNAKDM4E
SCHEMBL2013045 0.85 SMN1; SMN2 (0.49) MAOBMEN1KMT2ALMNASYK
SCHEMBL2011030 0.82 SMN1; SMN2 (0.48) MEN1KMT2ASYKMAPTKLK7
SCHEMBL13141346 0.81 SYK (0.47) MEN1KMT2ALMNASYKKDM4E
SCHEMBL2008607 0.79 SYK (0.43) MEN1KMT2ALMNASYKMAPT
SCHEMBL2011135 0.79 HPGD (0.47) HPGDMEN1KMT2ALMNAKDM4E
SCHEMBL8238491 0.79 SYK (0.61) MEN1KMT2ASYKMAPTALDH1A1
SCHEMBL2009004 0.78 HPGD (0.55) HPGDMAOBMEN1KMT2ALMNA
SCHEMBL2012647 0.78 HPGD (0.55) HPGDMAOBMEN1KMT2ALMNA
SCHEMBL2012428 0.78 HPGD (0.45) HPGDMEN1KMT2ALMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US disclosed
EP-1677783-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE Nicholas Piramal India Limited (IN) 2006-07-12 EP disclosed
WO-2005035495-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE NICHOLAS PIRAMAL INDIA LIMITED (IN) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE FGB, F13B, F2 HPGD 1551/4885MAOB 1394/4885MEN1 4472/4885
US-20070021489-A1 Fibrinogen receptor antagonists and their use FGB, F13B, F2 HPGD 1551/4885MAOB 1394/4885MEN1 4472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.